Concord Drugs Reports Strong Q2 FY27 Financial Results
Concord Drugs Ltd · Financial Result · 13 Nov 2026, 12:32 am
Concord Drugs Reports Strong Q2 FY27 Financial Results Concord Drugs approved its un-audited financial results for the quarter and half-year ended 30th Sep'26. On a consolidated basis, Q2 FY27 revenue from operations reached ₹2,080.95 lakhs compared to ₹1,027.85 lakhs in Q2 FY26. Consolidated net profit for the quarter rose sharply to ₹109.74 lakhs from ₹19.22 lakhs YoY, with basic and diluted EPS improving to ₹0.83 against ₹0.19 YoY. For H1 FY27, consolidated revenue stood at ₹4,175.65 lakhs and net profit reached ₹221.14 lakhs, outpacing share dilution effects.
Original exchange filing (PDF)
More announcements from Concord Drugs Ltd
- Board has Considered and approved quarterly results for 30th Sep,2026. · 13 Nov 2026
- Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Results for Quarter ending Sep 30, 2026. · 12 Nov 2026
- Annual general meeting -Scrutinizer''s Report · 01 Oct 2026
- Summary Proceedings of AGM · 01 Oct 2026
- Letter to members as per regulation 36(1)(b) · 08 Sept 2026
- Record date for Annual general meeting · 08 Sept 2026
- 31st Annual Report of the Company · 08 Sept 2026
- AGM to be held on 30.09.2026 at 09:00 AM · 08 Sept 2026
